Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ain cancer (which the Company will consider pursuing on a case by case basis if the "Hospital Exemption" is approved).

Progress in DCVax-Direct ProgramThe Company announced its unusually broad Phase I/II clinical trial approved by FDA for DCVax-Direct for all solid tumor cancers.  The Company initiated manufacturing arrangements for this trial in 2012.  The manufacturing involves novel, patented processes for partial maturation of the dendritic cells comprising the active agent of DCVax-Direct, and novel automation with proprietary machines and systems. 

The Company also entered into a Letter of Intent with Sarah Cannon Research Institute to partner in the execution of the Phase I/II trial in the US and UK.  Sarah Cannon has a network of 700 oncology doctors, who see 75,000 new cancer patients per year in the US and UK.

Progress in ManufacturingDue to levels of manufacturing demand significantly higher than originally projected for the Phase III brain cancer trial, the Company arranged for doubling of the manufacturing capacity dedicated to production of DCVax-L in the US.  The Company's contract manufacturer, Cognate BioServices, Inc. (Cognate) undertook the necessary construction for this doubling of capacity.

In Europe, the Company, its partner the Fraunhofer Institute, and Cognate completed the extensive regulatory processes and the final inspections for regulatory approval and certification for the manufacture of DCVax-L for the clinical trial in Germany – processes totaling more than 1-1/2 years of work.  The Company, Fraunhofer, Cognate and Kings College also began the 7-month processes for regulatory approvals and institutional approvals in both the UK and Germany to enable the manufacturing in Germany to supply DCVax-L for the clinical trial in the UK as well.  This German supply arrangement is in addition to the manufacturing under development in the UK.  Having two manufacturing lo
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
10. Palatin Technologies To Present At The 25th Annual ROTH Conference
11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... Yves Lionel Assant is,the new Chairman of Gerresheimer,s ... was already a member of the Supervisory Board. ... position for personal reasons. He,remains a member of ... & life science supply and services,company with market ...
... Stephen Simes, chief executive,officer of BioSante Pharmaceuticals, ... be featured in an exclusive interview with, http://www.wallst.net ... EDT. The interview,will be posted on http://www.wallst.net ... The interview will cover topics including BioSante,s ...
... Calif., Sept. 24 Today, the rights ... utilize PARI,s,eFlow electronic nebulizer for aerosol delivery ... of Corus Pharma in,August 2006, this is ... eFlow is featured prominently in the development ...
Cached Biology Technology:WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals 2Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca 2
(Date:10/14/2014)... Mount Sinai-led research team has discovered a new kind of ... a cell that lines liver blood vessels, according to a ... . The existence of such a cell type contradicts current ... embryo, and may hold clues to origins of, and future ... from a single cell into a complex being made up ...
(Date:10/14/2014)... CA – October 14, 2014 – Scientists from The ... from the National Institutes of Health (NIH) to lead ... virus-induced hemorrhagic fever disease in Africa. The study aims ... why some patients die, while others survive the inflection. ... understand the basic mechanism of how Lassa fever virus ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
Breaking Biology News(10 mins):Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Department of Energy,s Savannah River National Laboratory (SRNL) ... University to decrease mold growth in flooded homes ... by the Department of Homeland Security (DHS) through ... University asked SRNL and Tuskegee University to join ...
... JOLLA, Calif., July 14, 2010 Put simply, a tumor ... the cell cycle the cell,s process of duplicating itself ... of proteins tells other proteins what to do and when ... regulation fail, cell growth can get out of hand. A ...
... -- The 52nd meeting of the American Association ... - 22, 2010 in Philadelphia, PA. AAPM ... broadly-based scientific and professional discipline encompassing physics principles ... includes medical physicists who specialize in research that ...
Cached Biology News:SRNL works to decrease hazards from mold in water damaged homes 2New role for the JNK protein 2Nanotech medicine, tumor tracking, new technologies and more 2Nanotech medicine, tumor tracking, new technologies and more 3Nanotech medicine, tumor tracking, new technologies and more 4Nanotech medicine, tumor tracking, new technologies and more 5Nanotech medicine, tumor tracking, new technologies and more 6Nanotech medicine, tumor tracking, new technologies and more 7Nanotech medicine, tumor tracking, new technologies and more 8Nanotech medicine, tumor tracking, new technologies and more 9Nanotech medicine, tumor tracking, new technologies and more 10Nanotech medicine, tumor tracking, new technologies and more 11Nanotech medicine, tumor tracking, new technologies and more 12Nanotech medicine, tumor tracking, new technologies and more 13Nanotech medicine, tumor tracking, new technologies and more 14Nanotech medicine, tumor tracking, new technologies and more 15Nanotech medicine, tumor tracking, new technologies and more 16Nanotech medicine, tumor tracking, new technologies and more 17